Study of HCB101 for Advanced Solid Tumors or Non-Hodgkin Lymphoma
This study is testing a drug called HCB101, given through an IV, for people with advanced solid tumors or non-Hodgkin lymphoma that has returned or not responded to previous treatments. The main goals are to see if HCB101 is safe, what side effects might occur, and to find the highest dose that can be given without causing too many problems. Researchers also want to see if HCB101 can help shrink tumors. You might be able to join if you are at least 18 years old and have advanced cancer that has not responded to standard treatments. The study is currently unclear about its recruitment status and plans to enroll about 80 participants.
- Study design
- This is an open-label study, meaning you and your doctors will know you are receiving HCB101. It will involve about 80 participants and aims to find the right dose.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and maximum tolerated dose will be measured for 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
At a glance
Conditions
Where it's being run
8 sites across 6 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number/incidence and percentage of subjects with adverse events, including ADA.12 months
To evaluate the safety and tolerability of HCB101
- Number of subjects with MTD of HCB10112 months
To evaluate the safety and tolerability of HCB101